COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
The world has been suffering from the COVID-19 pandemic (officially declared by WHO in March 2020), caused by the severe acute respiratory β-coronavirus 2 (SARS-CoV-2) since the last week of December 2019. The disease was initially designated as a Public Health Emergency of International Concern on...
Lưu vào:
| Tác giả chính: | |
|---|---|
| Đồng tác giả: | |
| Định dạng: | BB |
| Ngôn ngữ: | en_US |
| Thông tin xuất bản: |
2023
|
| Chủ đề: | |
| Truy cập trực tuyến: | http://tailieuso.tlu.edu.vn/handle/DHTL/12726 |
| Từ khóa: |
Thêm từ khóa bạn đọc
Không có từ khóa, Hãy là người đầu tiên gắn từ khóa cho biểu ghi này!
|
| id |
oai:localhost:DHTL-12726 |
|---|---|
| record_format |
dspace |
| spelling |
oai:localhost:DHTL-127262023-03-29T07:43:12Z COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants Noor, Rashed Shareen, Saadia Billah, Muntasir COVID-19 SARS-CoV-2 Vaccines Variants Mutations Vaccine effectiveness Neutralizing antibodies The world has been suffering from the COVID-19 pandemic (officially declared by WHO in March 2020), caused by the severe acute respiratory β-coronavirus 2 (SARS-CoV-2) since the last week of December 2019. The disease was initially designated as a Public Health Emergency of International Concern on January 30, 2020. In order to protect the health of mass public, an array of research on drugs and vaccines against SARS-CoV-2 has been conducted globally. However, the emerging variants of SARS-CoV-2, i.e., Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants which evolved in late 2020 and the Omicron variant (B.1.1.529) which emerged in November 2021 along with its subvariant BA.2 which was first identified in India and South Africa in late December 2021, have raised the doubt about the efficiency of the currently used vaccines especially in terms of the consistent potential to produce neutralizing antibodies targeting the viral spike (S) protein. https://link.springer.com/article/10.1186/s42269-022-00787-z 2023-03-29T07:43:12Z 2023-03-29T07:43:12Z 2022 BB 2522-8307 http://tailieuso.tlu.edu.vn/handle/DHTL/12726 en_US Bulletin of the National Research Centre, Volume 46 (2022), Article number: 96 |
| institution |
Trường Đại học Thủy Lợi |
| collection |
DSpace |
| language |
en_US |
| topic |
COVID-19 SARS-CoV-2 Vaccines Variants Mutations Vaccine effectiveness Neutralizing antibodies |
| spellingShingle |
COVID-19 SARS-CoV-2 Vaccines Variants Mutations Vaccine effectiveness Neutralizing antibodies Noor, Rashed COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants |
| description |
The world has been suffering from the COVID-19 pandemic (officially declared by WHO in March 2020), caused by the severe acute respiratory β-coronavirus 2 (SARS-CoV-2) since the last week of December 2019. The disease was initially designated as a Public Health Emergency of International Concern on January 30, 2020. In order to protect the health of mass public, an array of research on drugs and vaccines against SARS-CoV-2 has been conducted globally. However, the emerging variants of SARS-CoV-2, i.e., Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants which evolved in late 2020 and the Omicron variant (B.1.1.529) which emerged in November 2021 along with its subvariant BA.2 which was first identified in India and South Africa in late December 2021, have raised the doubt about the efficiency of the currently used vaccines especially in terms of the consistent potential to produce neutralizing antibodies targeting the viral spike (S) protein. |
| author2 |
Shareen, Saadia |
| author_facet |
Shareen, Saadia Noor, Rashed |
| format |
BB |
| author |
Noor, Rashed |
| author_sort |
Noor, Rashed |
| title |
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants |
| title_short |
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants |
| title_full |
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants |
| title_fullStr |
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants |
| title_full_unstemmed |
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants |
| title_sort |
covid-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and its emerging variants |
| publishDate |
2023 |
| url |
http://tailieuso.tlu.edu.vn/handle/DHTL/12726 |
| work_keys_str_mv |
AT noorrashed covid19vaccinestheireffectivenessagainstthesevereacuterespiratorysyndromecoronavirus2sarscov2anditsemergingvariants |
| _version_ |
1787739398725435392 |